GlassScriptPhysician profile
Meshon Pouncil
NPI 1528766599
$5,398.28
in general payments reported to CMS, 2019-2025
20 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,043 · 2024: $2,201 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,386 · Education: $12.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,385.85 |
| Education | $12.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $975.65 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $771.77 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $771.02 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $603.38 | 2023-2024 | |
| Indivior INC. | $391.94 | 2023-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $352.21 | 2023-2024 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $297.02 | 2023-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $290.64 | 2023-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.19 | 2023-2024 | Caplyta |
| Lundbeck LLC | $267.35 | 2023-2024 | Rexulti, Brintellix |
| Supernus Pharmaceuticals, INC. | $120.18 | 2024 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $89.56 | 2023 | |
| Vanda Pharmaceuticals INC. | $70.20 | 2023-2024 | Hetlioz, Fanapt |
| Noven Therapeutics, LLC | $20.00 | 2023 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $19.92 | 2023 | Belsomra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $18.59 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $18.42 | 2024 | |
| Biogen, INC. | $15.74 | 2024 | |
| Tris Pharma INC | $13.68 | 2023 | Dyanavel Xr |
| Janssen Scientific Affairs, LLC | $6.82 | 2024 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meshon Pouncil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.